The Law Office of Joseph Klein is investigating the Board of Trubion Pharmaceuticals Inc. (NasdaqGM: TRBN) for possible breaches of fiduciary duty and other violations of state law regarding the sale of the company to Emergent BioSolutions Inc. (NYSE: EBS). Concerned shareholders should contact Joseph Klein directly at, or toll-free at: (877) STOK-180 (877-786-5180).

Under the terms of the transaction, each share of Trubion common stock will be converted into the right to receive $1.365 per share in cash and 0.1641 shares of Emergent stock. Based on Emergent's common stock price for the prior five days, the transaction values Trubion stock at $4.55 per share and the transaction at approximately $96.8 million. In addition, Trubion shareholders will receive one contingent value right ("CVR") per share, which will entitle the holder to receive cash payments based upon the achievement of certain milestones. The total potential aggregate value of the CVRs is $38.7 million over a three year period.

The investigation concerns whether the Trubion Board of Directors breached their fiduciary duties to Trubion stockholders by failing to adequately shop the Company before entering into this transaction and whether Emergent is underpaying for Trubion shares. At least one analyst set a price target for Trubion stock at $7.00 per share.

If you own shares of Trubion and wish to obtain additional information about this investigation, please contact Joseph Klein, Esq. directly, via email at, by telephone Toll Free: 877-STOK-180 (877-786-5180), or visit

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation.


Joseph Klein, Esq.1560 East 27th StreetBrooklyn, NY 11229Telephone: (718) 947-0005Fax: (718) 799-1443Toll Free: (877) STOK-180 (877-786-5180)

E-Mail: jk@jkleinlawfirm.comThe Web:

Copyright Business Wire 2010